A significant exchange has arisen in the Journal of Clinical Sleep Medicine concerning how to accurately diagnose insomnia in diabetes patients experiencing poor sleep. The dispute centers on whether these patients actually have insomnia or if their sleep issues are caused by an undiagnosed breathing disorder. This conversation involves researchers from the TURKAPNE cohort in Turkey and international critics, highlighting critical implications for the screening and treatment of sleep issues in individuals with type 2 diabetes.
Read More
The debate was sparked by a paper authored by Canan Gündüz Gürkan from Süreyyapaşa Chest Diseases Research and Training Hospital in Istanbul and Yüksel Peker, affiliated with several universities. Their study, which involved a nationwide Turkish cohort assessed for sleep-disordered breathing, found a link between diabetes mellitus and both increased prevalence and severity of a condition termed COMISA—co-morbid insomnia and sleep apnea. This finding is significant due to the detrimental effects seen in patients suffering from both disorders simultaneously.
COMISA affects a notable portion of patients in sleep clinics, with many presenting both chronic insomnia symptoms and objective signs of obstructive sleep apnea. Literature indicates that individuals with COMISA experience more severe daytime sleepiness, fatigue, diminished quality of life, and higher healthcare utilization compared to those with only one disorder. Treatment can also be more complex, as common therapies for sleep apnea may be difficult for insomnia patients to tolerate, and medications for insomnia may affect apnea patients negatively.
In response to the TURKAPNE study, Xu, Liu, and Liu challenged the findings, arguing that the analysis might have conflated true insomnia disorder—characterized by persistent sleep difficulties—with sleep issues resulting from apnea-related disruptions. This distinction is crucial because it informs treatment approaches; addressing only one disorder could lead to inadequate care.
The TURKAPNE researchers defended their original claims in a reply published on August 13, 2026, maintaining that their findings were clinically valid. They emphasized the complex interplay between diabetes and sleep disorders, noting various physiological links, such as obesity's role in both conditions and how sleep disturbances can lead to insulin resistance.
The exchange raises important clinical considerations. If diabetes is linked to combined sleep disorders, healthcare providers must consider both apnea and insomnia when evaluating sleep complaints in diabetic patients. Conversely, if sleep disruptions are misunderstood as insomnia, it may result in inadequate treatment protocols. Regardless, patients with diabetes facing sleep challenges should seek to understand their symptoms, as effective diagnostic tools and treatments are available.
The ongoing discussion in the Journal of Clinical Sleep Medicine underlines the need for clarity in distinguishing between these co-existing conditions, which is critical for improving patient outcomes in the growing population of those living with diabetes.